KVISTGAARD, Denmark, May 27 /PRNewswire/ -- Following the presentation of data with PROSTVAC(TM) - a promising, late-stage vaccine candidate for the treatment of advanced prostate cancer, Bavarian Nordic will be hosting a QA session at the ASCO Annual Meeting.

Time: Sunday, May 31st 2009 from 09 AM EDT to 10 AM EDT.

Location: Rosen Centre Hotel, 9840 International Drive, Orlando, Florida 32819

At the QA session, Bavarian Nordic's PROSTVAC(TM) team and President CEO, Anders Hedegaard will attend.

The QA session follows the presentation of final Phase 2 data with PROSTVAC(TM) at the 2009 ASCO Annual Meeting. The presentation will take place on May 30, 2009 at 5:00 PM EDT and will be held by Philip Kantoff, MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also principal investigator in the study.

Looking forward to seeing you there!

About PROSTVAC(TM)

PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development. PROSTVAC(TM) has the potential to extend survival with improved quality of life in patients with advanced prostate cancer.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com

Anders Hedegaard, +45-2320-3064